Myocardial Remodeling in Viral Heart Disease: Possible Interactions Between Inflammatory Mediators and MMP-TIMP System

Overview

Journal Heart Fail Rev

Date 2004 Jan 24

PMID 14739765

Citations 18

Authors

Matthias Pauschinger

Kumaran Chandrasekharan

Heinz-Peter Schultheiss

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinases (MMP), a family of proteases, are involved in the degradation of extracellular matrix proteins and hence in the determination of interstitial architecture. In the heart, MMPs have been found to play a significant role in the development of myocardial remodeling and congestive heart failure. Tissue inhibitors of matrix metalloproteinases (TIMPs) represent a family of proteins which are known to regulate the expression and activity of MMPs. TIMPs are endogenous physiological inhibitors of MMPs and their concomitant downregulation in heart failure suggests the existence of a critical balance between MMPs and TIMPs in the normal maintenance of myocardial interstitial homeostasis. In addition, cytokines regulate expression of both MMPs and TIMPs besides eliciting a direct effect on myocardial cell function. Therefore, myocardial inflammation may also contribute to the development of cardiac remodeling along with other stimuli like mechanical stress and humoral factors. Viral myocarditis, a predisposing factor for dilated cardiomyopathy, is a condition in which extent of intramyocardial inflammation is thought to determine the progression of disease. Inflammatory events in the heart following viral infection are speculated to be responsible for the transition of myocarditis to dilated cardiomyopathy. In viral myocarditis and other inflammatory heart diseases, the inflammatory cells and their battery of cytokines may also alter the myocardial MMP-TIMP system and eventually lead to dilation of the heart and ventricular dysfunction. The objective of this review is to present an overall picture of the inflammatory phase in viral myocarditis and discuss the possible interactions between inflammation and myocardial MMP profiles which may lead to the evolution of dilated cardiomyopathy.

Citing Articles

Farrerol prevents Angiotensin II-induced cardiac remodeling and .

He J, Xu D, Wang L, Yu X Front Pharmacol. 2023; 13:1079251.

PMID: 36686707 PMC: 9846078. DOI: 10.3389/fphar.2022.1079251.

Mechanisms and Therapeutic Strategies of Viral Myocarditis Targeting Autophagy.

Yu K, Zhou L, Wang Y, Yu C, Wang Z, Liu H Front Pharmacol. 2022; 13:843103.

PMID: 35479306 PMC: 9035591. DOI: 10.3389/fphar.2022.843103.

Luteolin Protects Cardiomyocytes Cells against Lipopolysaccharide-Induced Apoptosis and Inflammatory Damage by Modulating Nlrp3.

Liu Z, Gao S, Bu Y, Zheng X Yonsei Med J. 2022; 63(3):220-228.

PMID: 35184424 PMC: 8860941. DOI: 10.3349/ymj.2022.63.3.220.

Coxsackievirus A2 Leads to Heart Injury in a Neonatal Mouse Model.

Ji W, Zhu P, Liang R, Zhang L, Zhang Y, Wang Y Viruses. 2021; 13(8).

PMID: 34452454 PMC: 8402683. DOI: 10.3390/v13081588.

Effect of prostaglandin analogs: Latanoprost, bimatoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human trabecular meshwork endothelial cells.

Heo J, Ooi Y, Rhee D Exp Eye Res. 2020; 194:108019.

PMID: 32222455 PMC: 7262744. DOI: 10.1016/j.exer.2020.108019.

References

Borden P, Heller R . Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr. 1997; 7(1-2):159-78. DOI: 10.1615/critreveukargeneexpr.v7.i1-2.90. View

Corcoran M, Stetler-Stevenson W, Brown P, Wahl L . Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J Biol Chem. 1992; 267(1):515-9. View

Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T . Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001; 104(1):39-45. DOI: 10.1161/01.cir.104.1.39. View

Velasco G, Cal S, Ferrando A, Alvarez S, Nakano A, Arribas J . Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 2000; 60(4):877-82. View

Diwan A, Tran T, Misra A, Mann D . Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med. 2003; 3(2):161-82. DOI: 10.2174/1566524033361537. View

Kajita M, Kinoh H, Ito N, Takamura A, Itoh Y, Okada A . Human membrane type-4 matrix metalloproteinase (MT4-MMP) is encoded by a novel major transcript: isolation of complementary DNA clones for human and mouse mt4-mmp transcripts. FEBS Lett. 1999; 457(3):353-6. DOI: 10.1016/s0014-5793(99)01065-0. View

Martin A, Webber S, Fricker F, Jaffe R, Demmler G, Kearney D . Acute myocarditis. Rapid diagnosis by PCR in children. Circulation. 1994; 90(1):330-9. DOI: 10.1161/01.cir.90.1.330. View

Tracy S, Wiegand V, McManus B, Gauntt C, Pallansch M, Beck M . Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis. J Am Coll Cardiol. 1990; 15(7):1688-94. DOI: 10.1016/0735-1097(90)92846-t. View

Murphy G, Knauper V . Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol. 1997; 15(8-9):511-8. DOI: 10.1016/s0945-053x(97)90025-1. View

10.

Duivenvoorden W, Hirte H, Singh G . Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 1999; 17(1):27-34. DOI: 10.1023/a:1026404227624. View

11.

Zhang Y, McCluskey K, Fujii K, Wahl L . Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol. 1998; 161(6):3071-6. View

12.

Conca W, Kaplan P, Krane S . Increases in levels of procollagenase mRNA in human fibroblasts induced by interleukin-1, tumor necrosis factor-alpha, or serum follow c-jun expression and are dependent on new protein synthesis. Trans Assoc Am Physicians. 1989; 102:195-203. View

13.

Taipale J, Keski-Oja J . Growth factors in the extracellular matrix. FASEB J. 1997; 11(1):51-9. DOI: 10.1096/fasebj.11.1.9034166. View

14.

Pauschinger M, KNOPF D, Petschauer S, Doerner A, Poller W, Schwimmbeck P . Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation. 1999; 99(21):2750-6. DOI: 10.1161/01.cir.99.21.2750. View

15.

Saed G, Zhang W, Diamond M . Effect of hypoxia on stimulatory effect of TGF-beta 1 on MMP-2 and MMP-9 activities in mouse fibroblasts. J Soc Gynecol Investig. 2000; 7(6):348-54. View

16.

Ries C, Petrides P . Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler. 1995; 376(6):345-55. View

17.

Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B . Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 1999; 441(1):88-92. DOI: 10.1016/s0014-5793(98)01474-4. View

18.

Dostal D, Baker K . The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?. Circ Res. 1999; 85(7):643-50. DOI: 10.1161/01.res.85.7.643. View

19.

Staudt A, Schaper F, Stangl V, Plagemann A, Bohm M, Merkel K . Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation. 2001; 103(22):2681-6. DOI: 10.1161/01.cir.103.22.2681. View

20.

Baker A, Zaltsman A, George S, Newby A . Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 1998; 101(6):1478-87. PMC: 508704. DOI: 10.1172/JCI1584. View